Data from TRACER study of Vorapaxar, Merck’s investigational medicine for Cardiovascular Disease, presented at AHA
13 November 2011 | By Merck
TRACER did not achieve primary endpoint...
List view / Grid view
News
New data presented on Phase 3 trial of ELIQUIS® (apixaban)
13 November 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announced the results of the Phase 3 ADOPT trial...
Merck highlights pipeline progress and showcases novel innovations at R&D and Business Briefing
11 November 2011 | By Merck
Merck is hosting a R&D and Business Briefing...
Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide
11 November 2011 | By H. Lundbeck A/S (Lundbeck)
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a development and commercialisation agreement for up to five products in the psychiatry field, including aripiprazole depot formulation and OPC-34712 from Otsuka and up to three highly innovative earlier stage projects from Lundbeck.
Sanofi and Regeneron report positive preliminary Phase 2 program results
10 November 2011 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced positive preliminary results from the Phase 2 study program...
Syrris process chemistry systems support scale-up experiments in Brazil
10 November 2011 | By kdm communications limited
Zirkon Industria e Comercio Ltda in Brazil relies on an Atlas Calorimeter...
Lilly CEO Lechleiter outlines opportunities for improved health and economic growth in Asia-Pacific region
10 November 2011 | By Eli Lilly and Company
New trade agreements, effective public policies, and continued collaboration...
Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals
9 November 2011 | By Novartis
Novartis announced the appointment of Timothy Wright...
Abbott receives CE Mark for new hepatitis test
Abbott announced it has received CE Marking (Conformité Européenne) in the European Union to market a new, highly sensitive diagnostic test for detection of hepatitis B surface antigen (HBsAg). The test is performed on Abbott’s ARCHITECT® system. Hepatitis B is an inflammatory liver disease caused by the hepatitis B virus…
FDA accepts Roche’s New Drug Application for vismodegib in advanced form of skin cancer
9 November 2011 | By Roche
The vismodegib application has been granted priority review...
Daiichi Sankyo Brasil and Kyorin Pharmaceutical reach agreement in Brazil
8 November 2011 | By Daiichi Sankyo
Basic agreement reached for activities in Brazil related to the development and marketing of Imidafenacin...
AstraZeneca and Targacept announce first top-line Phase III results for TC-5214 as an adjunct treatment in patients with major depressive disorder
8 November 2011 | By AstraZeneca
Top-line results announced...
12-week on-treatment results from large Phase IIb study (COMMAND-1) of Bristol-Myers Squibb’s NS5A inhibitor daclatasvir support anti-HCV activity and safety profile observed in earlier studies
8 November 2011 | By Bristol-Myers Squibb Company
Study evaluated daclatasvir as add-on to peginterferon alfa/ribavirin (alfa/RBV)...
Novartis Phase III study shows ACZ885 helped substantially reduce steroid use in 45% of patients with serious form of childhood arthritis
7 November 2011 | By Novartis
New pivotal Phase III data announced...
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia
7 November 2011 | By GSK
Full results from ENABLE 1 and initial data from ENABLE 2 presented...
